GENFIT Announces Publication of the 2025 Universal Registration Document
MWN-AI** Summary
GENFIT, a biopharmaceutical company focused on rare and life-threatening liver diseases, announced the filing of its 2025 Universal Registration Document with the Autorité des marchés financiers (AMF) on April 7, 2026. This comprehensive document is publicly accessible at GENFIT’s website and on the AMF’s site, ensuring compliance with applicable regulations.
The 2025 Universal Registration Document encapsulates critical information, including the annual financial report, annual management report, and corporate governance report by the Board of Directors. Importantly, it also contains the Statutory Auditors' reports concerning the financial statements and associated agreements, along with a summary of fees paid to the auditors.
GENFIT emphasizes its commitment to addressing unmet medical needs in patients with rare liver conditions, specifically focusing on Acute on-chronic Liver Failure (ACLF) and related diseases. With over 20 years of experience, GENFIT has reshaped liver disease research and development, pioneering therapeutic innovations and diagnostic options. Their R&D activities have seen notable progress, exemplified by the 2024 FDA, EMA, and MHRA approvals of Iqirvo® (elafibranor), a treatment for Primary Biliary Cholangitis (PBC) that is now available in various markets.
In addition to therapy development, GENFIT has established a diagnostic franchise, notably with the NIS2+® test for detecting metabolic dysfunction-associated steatohepatitis (MASH). As a BCorp™ certified company since 2025, GENFIT operates from its headquarters in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA.
The document also contains forward-looking statements about the company’s expectations, operational risks, and uncertainties inherent in the biopharmaceutical industry, notably in relation to clinical trials, regulatory approvals, and market dynamics. For more details, inquiries can be directed to GENFIT's investor relations team.
MWN-AI** Analysis
GENFIT, a biopharmaceutical firm focused on rare liver diseases, has recently filed its 2025 Universal Registration Document with the Autorité des marchés financiers (AMF). This timely disclosure provides essential insights for investors considering their potential involvement with the company.
With GENFIT's ongoing focus on Acute on-chronic Liver Failure (ACLF) and its related conditions, the company positions itself within a niche medical segment that is ripe for advancement. The accelerating demand for innovative treatments in liver diseases underlines the potential for robust financial growth. Notably, the FDA's accelerated approval of elafibranor for Primary Biliary Cholangitis (PBC) signifies a critical milestone, enhancing market credibility and paving the way for commercial success.
Investors should note GENFIT’s diverse R&D initiatives, targeting not just liver diseases but also other critical areas like cholangiocarcinoma and urea cycle disorders. This variety may insulate the company against reliance on a single product or market segment. The company’s BCorp™ certification also appeals to socially responsible investors, marking GENFIT’s commitment to balancing profit and societal impact.
However, potential investors should remain vigilant about the inherent risks disclosed in their Universal Registration Document. The uncertainties surrounding drug development, regulatory approvals, and financial performance could lead to volatility in stock prices. Furthermore, the dependence on continual funding for R&D might strain resources, particularly amid ongoing market fluctuations.
In conclusion, GENFIT holds promise due to its innovative pipeline and market relevance. Yet, investors should weigh the potential rewards against the associated risks carefully. Conducting thorough due diligence and staying updated with the company’s regulatory and clinical developments is prudent in navigating this investment opportunity.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 07, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2025 Universal Registration Document with the Autorité des marches financiers (AMF; filing n° D.26-0221).
This document is available to the public free of charge in accordance with applicable regulations and may be viewed at and downloaded from GENFIT’s website at ir.genfit.com. The 2025 Registration Document is also available on the AMF’s website: www.amf-france.org.
GENFIT’s 2025 Universal Registration Document includes, in particular:
- The annual financial report,
- The annual management report,
- The Board of Directors’ report on corporate governance,
- The Statutory Auditors’ reports on the annual and consolidated financial statements and related-party agreements,
- The table summarizing the fees paid to the Statutory Auditors.
ABOUT GENFIT
GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries. Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements with respect to GENFIT. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2025 Universal Registration Document filed on April 03, 2026 (no. D.26-0221) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.
CONTACT
GENFIT | Investors
Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 | jean-christophe.marcoux@genfit.com
GENFIT | Media
Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr
Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com
Attachment
FAQ**
How does GENFIT's recent filing of the 2025 Universal Registration Document reflect its overall performance and strategic direction in the biopharmaceutical sector, particularly for Genfit GNFTF?
What potential challenges and opportunities does GENFIT anticipate in the upcoming regulatory approvals of its drug candidates, considering the competitive landscape of liver disease treatment for Genfit GNFTF?
In what ways might GENFIT's expansion into diagnostic products like NIS2+® impact its market positioning and revenue streams, especially for investors considering Genfit GNFTF?
How is GENFIT planning to leverage its recent FDA and EMA approvals for Iqirvo® (elafibranor) to maximize its market presence and stakeholder value, particularly related to Genfit GNFTF?
**MWN-AI FAQ is based on asking OpenAI questions about Genfit (OTC: GNFTF).
NASDAQ: GNFTF
GNFTF Trading
6.45% G/L:
$11.05 Last:
200 Volume:
$11.05 Open:
